Home/Filings/4/0001127602-25-006284
4//SEC Filing

Santos Esteban 4

Accession 0001127602-25-006284

CIK 0000318154other

Filed

Feb 20, 7:00 PM ET

Accepted

Feb 21, 8:07 PM ET

Size

9.8 KB

Accession

0001127602-25-006284

Insider Transaction Report

Form 4
Period: 2025-02-19
Santos Esteban
EVP, Operations
Transactions
  • Exercise/Conversion

    Nqso (Right to Buy)

    2025-02-198,7110 total
    Exercise: $156.35From: 2018-05-03Exp: 2026-05-03Common Stock (8,711 underlying)
  • Sale

    Common Stock

    2025-02-19$292.84/sh8,711$2,550,90371,546 total
  • Exercise/Conversion

    Common Stock

    2025-02-19$156.35/sh+8,711$1,361,96580,257 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    868.873
Footnotes (4)
  • [F1]These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
  • [F2]The price reported is an average price. The prices ranged from $292.7523 to $293.00 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
  • [F3]These shares include 667 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
  • [F4]These shares are acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

Issuer

AMGEN INC

CIK 0000318154

Entity typeother

Related Parties

1
  • filerCIK 0001677950

Filing Metadata

Form type
4
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 8:07 PM ET
Size
9.8 KB